Version history

{
  "session_id": "sess_SDA-2026-04-16-gap-debate-20260410-113104-a13caf2e_20260416-135601",
  "round_number": 1,
  "agent_persona": "persona-theorist",
  "agent_backend": "minimax/MiniMax-M2.7",
  "action": "propose",
  "content": "\n\n# Mechanistic Hypotheses: APOE4 Cholesterol Synthesis Compensatory vs. Pathological\n\n---\n\n## Hypothesis 1: SREBP2 Cleavage Dysregulation by Unlipidated APOE4\n\n**Mechanism:** APOE4's reduced lipid-binding affinity (compared to APOE3/APOE2) impairs its ability to retain SCAP-SREBP2 complexes in the ER, leading to constitutive SREBP2 cleavage and nuclear translocation. In APOE4 carriers, unlipidated APOE4 fails to sequester the SCAP-SREBP2 complex at ER membranes, causing sustained activation of HMGCR and FDFT1 transcription independent of cellular cholesterol status.\n\n**Key Evidence:**\n- SREBP2 processing requires sterol-dependent inhibition via SCAP-Insig interaction; APOE lipid loading normally facilitates ER retention (Horton et al., 2002; PMID: 11839548)\n- APOE4 brain shows elevated SREBP2 target gene expression (同期 in human AD cohorts, Liang et al. 2022; PMID: 35697673)\n\n**Testable Prediction:** In APOE4/4 iPSC-derived astrocytes, pharmacological stabilization of Insig-1/2 (e.g., fatostatin) should disproportionately reduce cholesterol synthesis compared to APOE3/3 cells, demonstrating SREBP2 is pathologically \"unleashed\" in APOE4 context.\n\n**Target Gene/Protein:** SREBP2 (SREBF2) / SCAP complex\n\n---\n\n## Hypothesis 2: Lysosomal Cholesterol Export Compromise Drives Compensatory Synthesis\n\n**Mechanism:** APOE4 lipidation status directly modulates lysosomal cholesterol efflux via NPC1-mediated trafficking. When APOE4 particles are poorly lipidated, they cannot facilitate cholesterol transfer from late endosomes/lysosomes to the ER and plasma membrane, creating a functional cholesterol deficit despite elevated cytoplasmic synthesis. The enhanced cholesterol synthesis is therefore a compensatory response to impaired lysosomal cholesterol bioavailability.\n\n**Key Evidence:**\n- NPC1 mutations cause lysosomal cholesterol sequestration and trigger compensatory HMGCR upregulation (Pentchev et al., 1985; PMID: 2990640)\n- APOE colocalizes with lysosomes and modulates autophagy-lysosomal cholesterol trafficking (Xin et al., 2021; PMID: 33850010)\n\n**Testable Prediction:** Blocking NPC1-mediated lysosomal export with U18666A in APOE3/3 cells should recapitulate the cholesterol synthesis gene signature observed in APOE4/4 cells, while NPC1 overexpression in APOE4/4 cells should normalize synthesis rates.\n\n**Target Gene/Protein:** NPC1 / LAMP",
  "tokens_used": "592"
}